Top Markets
#1 Pleasing Gold Pleasing Gold +1,501.62%
#2 Ontology Gas Ontology Gas +182.29%
#3 PulseChain PulseChain +57.88%
#4 Ontology Ontology +40.20%
#5 ConstitutionDAO ConstitutionDAO +36.86%
#6 Osmosis Osmosis +36.34%
#7 BOOK OF MEME BOOK OF MEME +31.61%
#8 Collect on Fanable Collect on Fanable +26.31%
#9 Neiro Neiro +25.71%
#10 Pump.fun Pump.fun +24.19%
Coin of the day
Pleasing Gold Pleasing Gold
설정
언어
한국어
통화
USD
테마
Icosavax, Inc. Icosavax, Inc.

Icosavax, Inc.

ICVX
주식 순위 #25854
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing... Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.
주가
$15.31
마지막 동기화: 2024-02-29
시가총액
$45.70M
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Icosavax, Inc. (ICVX)

카테고리

Healthcare
Icosavax, Inc. (ICVX)의 수익
2026 기준 수익 TTM: 0
Icosavax, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 수익 0과 동일입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Icosavax, Inc.의 수익 기록 (2026 ~ 2026)
연말 수익
연도 수익 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 수익
회사 수익 수익 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US